Top Page
Shandong Weigao Group Medical Polymer Co
(OTC:1066)
Shandong Weigao Group Medical Polymer Co (1066) vs. iShares MSCI Hong Kong ETF (EWH)
Shandong Weigao Group Medical Polymer Co Business Overview & Revenue Model
Shandong Weigao Group Medical Polymer Co Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.64B | 13.09B | 13.23B | 13.62B | 13.15B | 11.62B |
| Gross Profit | 3.30B | 6.58B | 6.64B | 7.31B | 7.35B | 6.46B |
| EBITDA | 1.64B | 3.14B | 3.55B | 4.38B | 3.75B | 3.09B |
| Net Income | 1.01B | 2.07B | 2.00B | 2.76B | 2.28B | 2.09B |
Balance Sheet | ||||||
| Total Assets | 36.14B | 34.76B | 33.67B | 33.20B | 30.37B | 27.34B |
| Cash, Cash Equivalents and Short-Term Investments | 9.65B | 8.32B | 7.33B | 7.49B | 7.13B | 6.14B |
| Total Debt | 5.51B | 4.19B | 4.17B | 4.49B | 4.14B | 4.32B |
| Total Liabilities | 10.45B | 9.42B | 9.68B | 9.75B | 9.46B | 8.95B |
| Stockholders Equity | 24.10B | 23.75B | 22.45B | 21.67B | 19.27B | 17.55B |
Cash Flow | ||||||
| Free Cash Flow | 881.57M | 2.19B | 2.11B | 1.10B | 1.92B | 1.70B |
| Operating Cash Flow | 881.57M | 2.79B | 2.80B | 2.21B | 3.04B | 2.70B |
| Investing Cash Flow | -1.56B | -1.10B | -1.39B | -2.57B | -1.48B | 423.22M |
| Financing Cash Flow | 833.29M | -1.60B | -2.16B | -1.02B | -547.92M | -1.79B |
Shandong Weigao Group Medical Polymer Co Technical Analysis
Shandong Weigao Group Medical Polymer Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | €10.63B | 17.45 | 23.40% | 2.90% | 6.51% | 4.85% | |
| ― | €2.16B | 14.04 | 3.76% | 6.67% | 21.39% | -0.57% | |
| ― | €4.85B | 10.21 | 17.42% | 3.83% | 6.87% | 18.37% | |
| ― | HK$5.26B | 25.41 | 10.31% | 1.00% | 14.06% | 3.02% | |
| ― | HK$18.25B | 31.57 | 24.57% | 0.78% | 13.58% | 24.59% | |
| ― | HK$25.46B | 12.08 | 8.34% | 4.23% | 0.74% | 2.13% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Shandong Weigao Group Medical Polymer Co Corporate Events
Shandong Weigao Group Medical Polymer Company Limited announced a potential transaction involving its subsidiary, Weigao Blood Purification, which intends to acquire 100% equity interest in WEGO Prefills Pharmaceutical Packaging Co., Ltd. This acquisition aims to create business synergies and expand the overall business scope of the Group. If completed, the transaction may be classified as a major and connected transaction under the Hong Kong Listing Rules, necessitating further disclosures.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Company Limited held an Extraordinary General Meeting on October 17, 2025, where all proposed resolutions were approved by shareholders. Key decisions included the approval of the 2025 H Share Incentive Scheme, the distribution of an interim dividend, and several amendments to the company’s articles of association. These resolutions are expected to enhance shareholder value and align the company’s governance structure with its strategic goals.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Co. has announced an interim dividend of RMB 0.0969 per share for the six months ending June 30, 2025, with a payment date set for November 21, 2025. This announcement reflects the company’s financial performance and commitment to shareholder returns, with implications for both domestic and international investors regarding withholding tax rates.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Company Limited has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement provides clarity on the company’s governance structure, potentially impacting its strategic direction and stakeholder confidence.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Company Limited announced an interim cash dividend of RMB 0.0969 per share for the six months ending June 30, 2025. The announcement includes a change in the date of the extraordinary general meeting, record date, and book closure period, with the payment date set for November 21, 2025. This dividend declaration reflects the company’s financial performance and commitment to returning value to shareholders, potentially impacting investor sentiment and market positioning.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Co., Ltd. has announced an extraordinary general meeting to discuss the approval and adoption of the 2025 H Share Incentive Scheme, which aims to grant share awards and manage the issuance of shares up to 4.5% of the company’s total shares. Additionally, the company plans to distribute an interim dividend and reappoint Mrs. Meng Hong as an independent non-executive director, reflecting its commitment to shareholder value and governance.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Company Limited has announced a rescheduling of its extraordinary general meeting (EGM) from October 16, 2025, to October 17, 2025, to allow more time for finalizing the circular to be sent to shareholders. The book closure period for determining shareholders’ entitlement to attend and vote at the EGM has also been adjusted, impacting the timeline for share transfers and dividend entitlements.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Company Limited announced proposed amendments to its Articles of Association to align with recent legal and regulatory changes, including the flexibility to manage treasury shares and facilitate electronic voting in shareholder meetings. Additionally, the company plans to implement full circulation of its H shares, converting 48,300,000 unlisted shares into H shares, pending necessary approvals, which could enhance liquidity and market presence.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Company Limited announced the resignation of Ms. Yan Xia from her roles as vice chairman and non-executive director, effective 8 October 2025, as she pursues personal development opportunities. The company assured stakeholders that her departure will not affect the board’s statutory quorum or the normal operations of the company, and expressed gratitude for her contributions.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Co., a prominent player in the medical device industry, specializes in the research, development, production, and sale of a diverse range of medical products, including orthopaedic, interventional, pharma packaging, and blood management products, alongside operating a financing business. In its latest earnings report for the first half of 2025, the company reported a marginal revenue increase of 0.1% to approximately RMB6.64 billion, while net profit attributable to shareholders saw a decline of 9% to RMB1.01 billion compared to the same period last year. The company maintained a stable financial position with a sound cash flow, despite facing challenges such as increased production costs and foreign exchange losses. Key financial highlights include a slight growth in the medical device segment and a decrease in the orthopaedic and interventional segments. The company also emphasized its commitment to research and development, with significant investments in new patents and product registrations, aiming to enhance its product mix and maintain a competitive edge in the market. Looking ahead, Shandong Weigao Group remains focused on expanding its market presence both domestically and internationally, leveraging its strategic initiatives in product innovation, cost management, and market expansion to sustain growth and strengthen its market position.
Shandong Weigao Group Medical Polymer Co., Ltd. has made an overseas regulatory announcement in compliance with the disclosure requirements of the Hong Kong Stock Exchange. The announcement, published on the Shanghai Stock Exchange’s website, reflects the company’s ongoing commitment to transparency and regulatory compliance, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1066) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Co., Ltd. has made an overseas regulatory announcement in compliance with the disclosure requirements of the Hong Kong Stock Exchange. The announcement, published on the Shanghai Stock Exchange’s website, reflects the company’s adherence to regulatory standards, potentially impacting its transparency and positioning in the market.
The most recent analyst rating on (HK:1066) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Co., Ltd. announced an overseas regulatory update, as per the disclosure requirements of the Hong Kong Stock Exchange. The announcement, published on the Shanghai Stock Exchange’s website, reflects the company’s compliance with regulatory standards, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1066) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Company Limited has announced the proposed adoption of a 2025 H Share Incentive Scheme, aimed at attracting and retaining key contributors to the company’s long-term growth. The scheme is designed to align the interests of participants with those of the company and its shareholders, enhancing the company’s long-term remuneration strategy and overall performance. The adoption of this scheme is subject to shareholder approval at an upcoming extraordinary general meeting.
The most recent analyst rating on (HK:1066) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Company Limited reported a slight increase in revenue for the first half of 2025, reaching approximately RMB6.64 billion, a 0.1% rise from the previous year. However, the company’s net profit saw a decline of 9% to approximately RMB1.01 billion, attributed to increased costs and expenses. The board proposed an interim dividend of RMB0.0969 per share, pending shareholder approval. The financial results indicate challenges in maintaining profit margins despite stable revenue, reflecting the competitive pressures and cost management issues within the industry.
The most recent analyst rating on (HK:1066) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Co has announced an interim cash dividend of RMB 0.0969 per share for the six months ending June 30, 2025. This announcement reflects the company’s financial performance and commitment to returning value to its shareholders, with the payment date set for November 21, 2025.
The most recent analyst rating on (HK:1066) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Co has announced a board meeting scheduled for August 27, 2025, to discuss and approve the unaudited interim results for the first half of the year and consider the declaration of an interim dividend. This meeting is significant as it will provide insights into the company’s financial performance and potential shareholder returns, impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.40 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.